PLAQUETEC LIMITED

Comprehensive Financial Health Assessment: PLAQUETEC LIMITED

1. Financial Health Score: C (Stable but Under Observation)

Explanation: Assessing PlaqueTec Limited presents a unique diagnostic challenge. Because the company files as a "Small" entity under UK regulations, it is legally exempt from publishing detailed profit and loss figures or a cash flow statement on the public register. Without this "blood work," a complete quantitative diagnosis is impossible. However, based on the available metadata, corporate longevity, and governance structure, the company is stable but requires observation. The nominal share capital and the nature of the biotech industry suggest this is a business sustained by periodic capital injections rather than organic, healthy cash flow from trading—common for clinical research firms, but indicative of a higher-risk financial constitution.

2. Key Vital Signs

• Corporate Pulse (Longevity): Incorporated in 2007, the company has survived for 17 years. In the high-mortality world of biotech startups, this is an excellent vital sign, indicating resilience and the ability to secure ongoing funding.
• Blood Pressure (Capital Structure): Share capital stands at a mere £25. This is the absolute minimum required to form a Private Limited Company. While legally sound, it reveals that the company is not retaining earnings within traditional share structures; rather, it is almost certainly relying on shareholder loans, venture capital, or grant funding to keep the lights on.
• Organ Health (Governance & Compliance): The company's regulatory pulse is strong. Accounts and confirmation statements are not overdue, meaning there are no immediate symptoms of administrative distress or impending dissolution.
• Genetic Profile (Industry & Leadership): Operating in "Other professional, scientific and technical activities" (specifically cardiovascular biomarker research), the company has a high-risk, high-reward "genetic" makeup. The board features highly specialized individuals, including a Consultant Cardiologist and a director with a medical doctorate, which is precisely the specialist care this type of corporate patient needs.
• Anomaly Detected (Filing Dates): The last accounts made up date is listed as 2026-01-31. This is highly unusual and likely a data anomaly or a recently extended accounting reference date. This must be monitored to ensure the company does not fall out of compliance.

3. Diagnosis

The financial data reveals a company that is in a prolonged "clinical trial" phase. PlaqueTec is not displaying the healthy cash flow of a mature, trading business; instead, it exhibits the vital signs typical of a research-intensive biotech firm. The £25 share capital is a classic symptom of a startup that operates through director loans and external seed funding rather than generating its own revenue.

The ownership structure—split between two individuals (Moynihan and Stapleton) each holding between 25% and 50% of voting rights—suggests tight, concentrated control. This means financial decisions can be made swiftly, but the company's financial health is entirely dependent on the continued willingness and financial capacity of these key individuals to fund operations. The lack of published net current assets or P&L reserves means we cannot rule out underlying symptoms of distress, such as cash burn or accumulated losses, but the 17-year survival rate points to effective, ongoing financial life support from its backers.

4. Recommendations

• Improve Diagnostic Transparency: While legally exempt, voluntarily filing fuller accounts would improve the company's financial "bedside manner." Transparent financials build trust with potential future investors, partners, and creditors.
• Monitor the Cash Burn Rate: For a biotech firm, cash is the oxygen supply. Management must rigorously monitor the rate at which cash is consumed and ensure that funding rounds or grant applications are initiated well before the patient starts gasping for air.
• Review Capital Structure: The £25 share capital is structurally bare. As the company matures and potentially brings in further equity investment, the directors should consider a capital reorganization to reflect the true equity value injected into the business, which provides a healthier balance sheet presentation.
• Verify Filing Anomalies: The directors should immediately review the Companies House filing history to ensure the 2026 accounting reference date is correct and not an error that could lead to unexpected penalties or a strike-off threat.